Thursday, March 28, 2013
Publication and contact
Sirtuin 1 (SIRT1)
In vitro studies identified a SIRT1 mutation that could be
associated with type 1 diabetes. Genotyping and sequencing identified a
leucine to proline substitution at residue 107 of SIRT1 in four family members
with type 1 diabetes and one with ulcerative colitis (UC). In b
cells, expression of the mutant SIRT1 disrupted normal SIRT1 activity
and increased production of cytokines, chemokines and nitric oxide compared
with expression of wild-type SIRT1. In myoblasts isolated from healthy
controls, transduction with the SIRT1 mutant caused insulin resistance. Next
steps include developing SIRT1 activators to treat type 1 diabetes.
Elixir Pharmaceuticals Inc.'s
EX-527, an oral SIRT1
inhibitor, is in Phase II testing to treat Huntington's disease (HD).
GlaxoSmithKline plc's GSK2245840 SIRT1 activator
is in Phase II testing to treat psoriasis. The compound completed Phase I/II
trials for type 2 diabetes, but the pharma said it is no longer pursuing that
indication with the compound.
Ildong Pharmaceutical Co. Ltd.'s
SIRT1 activator, ID2244, is in preclinical
development to treat metabolic syndrome.
Published online March 28, 2013
Patent and licensing status
Biason-Lauber, A. et al.
Cell Metab.; published online March 5, 2013;
Contact: Marc Y. Donath, University Hospital Basel, Basel,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]